XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells

Raghida A. Bukhalid(Mersana Therapeutics (United States)), Timothy B. Lowinger(Mersana Therapeutics (United States))
Clinical Cancer Research
March 3, 2025
Cited by 32


Related Papers

No related papers found

Powered by citation graph analysis